Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study investigates relationship between fatty liver prognosis and body composition analysis result based on non-contrast low dose CT in patients with fatty liver disease.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| non-contrast low-dose abdomen CT | Experimental | non-contrast low-dose abdomen CT (target effective dose: < 1.5 mSv). CT based body composition analysis is performedd with commercially available automatic segmentation software (DeepCatch, Medical IP, South Korea). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Non-contrast low-dose abdomen CT | Diagnostic Test | target effective dose: < 1.5 mSv It is performed twice in 6-month interval. |
|
| Measure | Description | Time Frame |
|---|---|---|
| relationship between body composition analysis result from CT and liver fat fraction | relationship between visceral fat volume fraction (obtained from CT analysis using automatic body segmentation, unitless (visceral fat fraction = visceral fat volume/total body volume)) and CAP value of fibroscan | 6 month after CT acquisition |
| Measure | Description | Time Frame |
|---|---|---|
| ratio of appropriate non-contrast low dose abdomen CT acquisition & analysis | Number of CT scan with effective dose < 1.5 mSv AND successful automatic body composition analysis (without manual editing) divided by total number of CT scan | 6 month after CT acquisition |
| relationship between body composition analysis result from CT and hepatic fibrosis |
| Measure | Description | Time Frame |
|---|---|---|
| incidence of incidental finding | incidentally detected findings on low-dose abdomen CT | 6 month after CT acquisition |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jeong Min Lee, MD | Professor | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Seoul National University Hospital | Seoul | 03080 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D005234 | Fatty Liver |
| ID | Term |
|---|---|
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Fibroscan | Diagnostic Test | Fibroscan is performed within a week of low-dose CT. It is used as a reference standard of hepatic fibrosis and steatosis. |
|
| bioelectrical impedance analysis (BIA) | Diagnostic Test | BIA test is performed on the same day of low-dose CT. Commercially available model (Inbody 270) is used. |
|
|
relationship between visceral fat volume fraction (CT analysis using automatic body segmentation, unitless (visceral fat fraction = visceral fat volume/total body volume)) and liver stiffness value of fibroscan |
| 6 month after CT acquisition |
| agreement between body composition analysis result from CT and bioelectrical impedance analysis (Inbody test) | agreement of visceral fat, subcutaneous fat, muscle amount between CT based body composition and Inbody test results | 6 month after CT acquisition |